Atyr PHARMA (NASDAQ:ATYR - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05, Zacks reports.
Atyr PHARMA Stock Performance
Shares of ATYR stock traded down $0.02 during trading on Friday, reaching $3.97. The company had a trading volume of 2,401,773 shares, compared to its average volume of 1,313,086. The firm's 50 day simple moving average is $3.65 and its two-hundred day simple moving average is $3.07. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA has a one year low of $1.42 and a one year high of $4.66. The company has a market capitalization of $333.25 million, a PE ratio of -4.22 and a beta of 0.98.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on ATYR shares. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday. Leerink Partners started coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price objective for the company. Cantor Fitzgerald started coverage on Atyr PHARMA in a research report on Monday, January 6th. They set an "overweight" rating for the company. Finally, Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Atyr PHARMA presently has an average rating of "Buy" and an average target price of $18.60.
View Our Latest Stock Report on ATYR
Atyr PHARMA Company Profile
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Articles
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
